Sorry, your browser is out of date. To view this page correctly, please install a modern browser (Microsoft Edge, Firefox or Google Chrome).
SAI - Detailed view
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
XEVUDY Inf Konz 500 mg/8ml Durchstf 8 ml
Drug
Xevudy, Konzentrat zur Herstellung einer Infusionslösung
Behandlung von COVID-19
08.03.0. – antivirals
HAM – Human medicine
KOINF – Concentrate for solution for infusion
BT – biological medicines
A – Dispensed once only on prescription by a physician or veterinarian (A)
Z – approved
1/14/2022
3/18/2029
Dosage strength
Xevudy, Konzentrat zur Herstellung einer Infusionslösung
Behandlung von COVID-19
01
Z – approved
Package
7680684710018
No information made available
A/R – Authorised / referenced
1 vial(s)
001
Z – approved
Declaration
Component
500 mg sotrovimabum
histidinum
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
methioninum
aqua ad iniectabile
histidini hydrochloridum monohydricum
saccharum
polysorbatum 80
methioninum
aqua ad iniectabile
Authorisation holder
7601001000674
GlaxoSmithKline AG
Talstrasse 3
3053 Münchenbuchsee (BE)
Talstrasse 3
3053 Münchenbuchsee (BE)
Date of revision of the text
8/1/2024
Please log in as a company employee using your Swiss-Rx-Login. For further information please see the FAQ.
Data source: Swissmedic, *authorisation holder, **Refdata foundation, ***FOPH.